임상 한눈에 보기

• 12건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 7건 · 완료/종료 2건
• Phase: Phase 2 · Phase 3 · Phase 2, Phase 3 · Phase 1, Phase 2
• Status: Enrolling by invitation · Recruiting · Active, not recruiting…
• 주요 endpoint: Incidence of ocular adverse events and any serious adverse events in the study eye · Fellow eye substudy: Incidence of ocular adverse events and any serious adverse events in the fellow eye · Change from baseline in best corrected visual acuity (BCVA) in the study eye · Change from baseline in Central Retinal Thickness (CRT) in the study eye · Number of supplemental anti-VEGF injections in the study eye
• 등록 대상자(표본 합산): 약 4,007명
• 핵심: Disease-specific study endpoint: -7.6. Excessive vascular endothelial growth factor (VEGF) plays a key part in promoting…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.